Literature DB >> 21193861

Pegloticase.

Naomi Schlesinger, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21193861     DOI： 10.1038/nrd3349

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Febuxostat.

Authors:  Eliseo Pascual; Francisca Sivera; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

2.  Development of the gout tophus. An hypothesis.

Authors:  D G Palmer; J Highton; P A Hessian
Journal:  Am J Clin Pathol       Date:  1989-02       Impact factor: 2.493

3.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 4.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

5.  Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Authors:  John S Sundy; Nancy J Ganson; Susan J Kelly; Edna L Scarlett; Claudia D Rehrig; William Huang; Michael S Hershfield
Journal:  Arthritis Rheum       Date:  2007-03

6.  Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.

Authors:  H Ralph Schumacher; John S Sundy; Robert Terkeltaub; Howard R Knapp; Scott J Mellis; Neil Stahl; George D Yancopoulos; Yuhwen Soo; Shirletta King-Davis; Steven P Weinstein; Allen R Radin
Journal:  Arthritis Rheum       Date:  2012-03

Review 7.  Gout.

Authors:  Pascal Richette; Thomas Bardin
Journal:  Lancet       Date:  2009-08-17       Impact factor: 79.321

8.  Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Authors:  John S Sundy; Michael A Becker; Herbert S B Baraf; Andre Barkhuizen; Larry W Moreland; William Huang; Royce W Waltrip; Allan N Maroli; Zeb Horowitz
Journal:  Arthritis Rheum       Date:  2008-09
  8 in total
  20 in total

1.  Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Authors:  Xiaolan Yang; Yonghua Yuan; Chang-Guo Zhan; Fei Liao
Journal:  Drug Dev Res       Date:  2011-12-29       Impact factor: 4.360

2.  Larger companies dominate cancer companion diagnostic approvals.

Authors:  Charles Schmidt
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

Review 3.  Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives.

Authors:  Gregor Fuhrmann; Jean-Christophe Leroux
Journal:  Pharm Res       Date:  2013-11-02       Impact factor: 4.200

Review 4.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

5.  A Numerical Approach for Kinetic Analysis of the Nonexponential Thermoinactivation Process of Uricase.

Authors:  Jing Wu; Xiaolan Yang; Deqiang Wang; Xiaolei Hu; Juan Liao; JingJing Rao; Jun Pu; Chang-Guo Zhan; Fei Liao
Journal:  Protein J       Date:  2016-08       Impact factor: 2.371

Review 6.  Beyond Medical Treatment: Surgical Treatment of Gout.

Authors:  Jonathan Carcione; Shari Bodofsky; Brian LaMoreaux; Naomi Schlesinger
Journal:  Curr Rheumatol Rep       Date:  2020-11-24       Impact factor: 4.592

Review 7.  Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.

Authors:  Allison Guttmann; Svetlana Krasnokutsky; Michael H Pillinger; Adey Berhanu
Journal:  Ther Adv Drug Saf       Date:  2017-09-13

8.  Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.

Authors:  Sung In Lim; Young S Hahn; Inchan Kwon
Journal:  J Control Release       Date:  2015-04-07       Impact factor: 9.776

9.  Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy.

Authors:  Yi Shi; Ting Wang; X Edward Zhou; Qiu-Feng Liu; Yi Jiang; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2019-06-28       Impact factor: 6.150

10.  Tracking T-cells in vivo with a new nano-sized MRI contrast agent.

Authors:  Li Liu; Qing Ye; Yijen Wu; Wen-Yuan Hsieh; Chih-Lung Chen; Hsin-Hsin Shen; Shian-Jy Wang; Haosen Zhang; T Kevin Hitchens; Chien Ho
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.